Systematic treatment in gastric cancer patients with overt bleeding: A propensity score matching analysis

Table 1 Baseline characteristics of patients before propensity score matching, n (%)

Variables	Patients with OBBT (n = 41)	Patients without OBBT (n = 130)	P value	SMD
Gender
Male	30 (73.2)	94 (72.3)	0.914	0.019
Female	11 (26.8)	36 (27.7)
Age (range, years)	65 (47-85)	64 (29-83)	0.003	0.486
BMI (range, kg/m2)	21.0 (15.2-27.2)	22.0 (16.0-33.6)	0.153	0.259
Weight loss (range, %)	8.3 (0-37.4)	5.7 (0-26.0)	0.044	0.399
Smoking history
Yes	15 (36.6)	60 (46.2)	0.282	0.195
No	26 (63.4)	70 (53.8)
Drinking history
Yes	7 (17.1)	17 (13.1)	0.521	0.112
No	34 (82.9)	113 (86.9)
1Chronic disease
Yes	16 (39.0)	42 (32.3)	0.428	0.141
No	25 (61.0)	88 (67.7)
ECOG-PS
0	1 (2.5)	5 (3.8)	0.010	0.473
1	32 (78.0)	119 (91.5)
2	8 (19.5)	6 (4.6)
Primary tumor location
Body	15 (36.6)	74 (56.9)	0.061	0.429
Pylorus	13 (31.7)	24 (18.5)
Cardia	13 (31.7)	32 (24.6)
Cancer stage (AJCC 8th)
Stage III	9 (22.0)	33 (25.4)	0.656	0.081
Stage IV	32 (78.0)	97 (74.6)

¹Consisting of hypertension, coronary heart disease, cerebral infarction, diabetes, chronic renal failure, and chronic liver disease.

OBBT: Overt bleeding before treatment; SMD: Standard mean difference; BMI: Body mass index; ECOG-PS: Eastern Corporative Oncology Group Performance Status; AJCC: American Joint Committee on Cancer.